Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

Completed · Phase 1

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.

Key facts

Study ID

NCT00231166

Run by

Novartis Pharmaceuticals

People needed

33

Starts

2005-09-01

Expected to finish

2009-05-01

Last updated by the study team

2018-10-11

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical Diagnosis of MM requiring treatment
• Refractory or Relapsed Disease
• At least one prior treatment regimen
• Male or Female
• >18 years of age

You may not qualify if…

• Prior Allogeneic bone marrow transplant (prior autologous transplant allowed)
• Intracranial disease or epidural disease
• Clinically significant cardiac dysfunction or other significant organ dysfunction

Where it is running

• Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102 — Boston, Massachusetts, United States
• St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer — New York, New York, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 — Philadelphia, Pennsylvania, United States
• Fred Hutchinson Cancer Research Center Dept. of FHCRC — Seattle, Washington, United States
• Novartis Investigative Site — Herston, Queensland, Australia
• Novartis Investigative Site — Prahran, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.